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Experience In hepatic resection for metastatic 
colorectal cancer: Analysis of clinical and 
pathologic risk factors 
Timothy J. Gayowski, MD, Shunzaburo Iwatsuki, MD, PhD, Juan R. Madariaga, MD, 
Rick Selby, MD, Satoru Todo, MD, William Irish, MSc, and Thomas E. Starzl, MD, PhD, 
Pittsburgh. Pa. 
Background. The selection oj /Jatients Jor resective themp), oj hepatic coLorecta! metastases 
l"emains crmlro['erszal. A number oj cLmical and pathologIC prognostIc risk Jacton have been 
va7"iably reported 10 influence survival. 
Methods. Between january 7987 and December 7997, 204 patients underwent curative hepatIc 
resection Jor metastatic coLorectaL cancer. Fourteen clinical and pathoLogic determinants jJTevz()usLy 
reported to influence outcome were examined retrospectiueLy. This Led to a proposed TNlvI staging 
s},stem Jm' metastatic coLorectal cancer (m TNJ\lI) . 
Results. No operative deaths occurred (death within 7 month). Overall 7-, 3-, and 5-year 
survivals were 97%, 43%, and 32%, respectively. Gender, Dukes' classification, site of primary 
colorectal canceT, histologic dijJerentiation, size of metastatic tumor, and intraoperative blood 
transfusion requiTement were not statistically significant prognostic factors (p> 0.05). Age of 60 
years or more, intavaL of 24 months OT less between colorectal and hepatic Tesection, four or more 
gross tumors, bilobar invoLvement, positive resection margin, Lymph node involvement, and direct 
inva.\1U1l tu adjacent urgans were significant /)OOT prognostic facton (p < 0.05). In the absence of 
nodal disease aT direct invasion, patients with unilobaT solitary tumor of any size, or unilobaT 
multiple tumon of 2 cm or smaller (stages 1 and 11) had the highest survival rates of 93% at 7 
year, 68% at 3 years, and 67% at 5 years. UnilobaT disease with multiple lesions greater than 2 cm 
(stage Ill) resulted in 7-,3-, and 5-year survivals of 98%, 45%, and 28%, respectively. Patients 
with hilobar involvement (multiple tumors, any size, or a single large metastasis) (stage IVA) had 
surVIval rates of 88% at 7 year, 28% at 3 years, and 20% at 5 years (p < 0.00007). Patients with 
nodal involvement or extrahepatic disease (stage IVB) experienced the poorest outcome with 1-, 
3-, and 5-year survivals of 80%, 72%, and 0%, respectively (p < 0.00007). 
Conclusions. The proposed m TNNI staging system appears to be useful in pTedicting the 
outcomes after hepatic resection of metastatic colorectal tumors. (SURGERY 7994; 776:703-17.) 
From the Department of Surgery, Unwersity of Pittsburgh Medical CenteT and Veterans 
Administration Medical CenteT, Pittsburgh, Pa. 
ALTHOUGH IT IS CLEAR that hepatic resection for met-
astatic colorectal cancer can be performed quite safely, 
there is still controversy regarding patient selection. I"} 
Previous studies reported that 5-year survival rates 
(rarely observed \,vil.hout resection) rarige frolll l6% to 
52%.I"I} Man\" have ;Irlr!rrsserl the in HlI'rrwc of various 
clinical and pathologic parameters on the outcome or 
resective therapy, but the results vary considerably from 
study to study. 
We have reexamined our 204 consecutive patients 
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who underwent hepatic resection for colorectal metas-
tases during the last 11 years to identify clinical and 
pathologic prognosticators. 
Metastatic tumor characteristics were further exam-
ined by utilizing a TNM staging system modified from 
the International Union Against C:1llC"cr (LICe) and 
The American Joint Committee on Cancer (AJCC) 
recommendations for primary hepatobiliary tumors. 14 
The results of this analysis will hopefully provide addi-
tional guidance identifying the patients most likely to 
benefit from surgical intervention and also help identify 
those at high risk for recurrence. 
CASE MATERIAL AND METHODS 
Patients. At the University of Pittsburgh Medical 
Center 204 patients underwent hepatic resection for 
metastatic colorectal carcinoma during an ll-year pe-
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Fig. 1. Overall and disease-free survival rates of 204 patients after hepatic resection for metastatic colorectal 
cancer. 
riod from January 1981 to December 1991. These were 
all attempts at curative resection. The 130 men and 74 
women ranged in age from 28 to 79 years with a mean 
age of 58.5 years (median, 60 years). Patient follow-up 
as of December 1993 ranged from 24 to 130 months 
(median, 69 months). 
The interval between resection of the colorectal pri-
mary tumor and hepatic resection ranged from -6 
months (primary not discovered until after resection) to 
228 months with a median of 16 months. Two patients 
had Dukes' A primary tumors, and 53 had Dukes' B. 
Dukes' C tumors comprised the largest group with 93 
patients, and 56 patients had synchronous hepatic me-
tastases. Most patients with Dukes' D tumors (syn-
chronous metastases) underwent hepatic resection 
within the first 3 months; however, nine patients were 
not referred or evaluated until after this interval. 
.vIajor hepatic resections were performed in 171 pa-
tients (84%). Of the 115 patients having right or left 
lobectomies. 96 patients underwent standard lobecto-
mies. 15 had wedge resections in addition to lobectomv, 
three patients had "extended" lobectomies, and one pa-
tient had multiple wedge resections with a right lobec-
wm\'. Fifh--five trisegmentectomies were performed 
with -+7 right and 8 left. 8 
:'-Jinety-one patients had solitarv lesions. 15 of which 
had minor resections and 76 required either lobectomy 
(n = 54) or trisegmentectomy (n = 22). Multiple me-
tastases were resected in the remaining 113 patients 
with 40 having four or more lesions (range, 4 to 11 le-
sions). 
Methods, A retrospective review of all available in-
patient and outpatient records including operative and 
surgical pathology reports was performed. Patient fol-
low-up and outcome were documented by clinical visits, 
telephone interview, or correspondence. 
The following clinical and pathologic risk factors 
were examined for prognostic influence: gender, age, 
interval between colorectal and hepatic resection, Duke's 
stage, site of colorectal primary tumor, histologic differ-
entiation of the secondary tumor, number of metastases, 
tumor size (largest nodule diameter), unilobar or bilo-
bar disease, type of hepatic resection, margin of resec-
tion. involvement of lymph nodes or contiguous struc-
tures, and intraoperative blood transfusion. 
Statistical analysis, Survival time was calculated 
from the date of hepatic resection until death and dis-
ease-free survival from the date of hepatic resection un-
til the time of tumor recurrence. Survival curves were 
generated bv using the Kaplan-:vleier 'product-limit) 
method and were compared by using the generalized 
\Vilcoxon (Breslow) test. L'nivariate Cox's proportional 
f 
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Table I. Clinical risk factors and primary tumor characteristics for overall and disease-free survival 
So. of Ouerall sUITlual f%.1 
0/ patients 7 VI" 3 yl" 
Overall 204 91 45 
Gender 
Male 130 92 47 
Female 74 89 43 
Age 
<60 yr 96 93 51 
~SM yr 108 89 40 
Disease-free interval 
-6 to 3 mo 47 89 37 
4 to 12 mo 42 88 48 
13t024mo 49 86 41 
25 to 48 rna 43 98 46 
49 to 228 rna 23 96 65 
524 rna 138 88 42 
>24 rna 66 97 52 
Primary stage 
Dukes' A and B 55 87 63 
Dukes' C 93 92 40 
Dukes'D 56 91 37 
Site of primary tumor 
Anorectal 56 89 47 
Sigmoid/left colon 105 93 47 
Transverse/right colon 43 86 40 
hazards model was used to calculate the relative risk 
(RR) of mortality and tumor recurrence and 95% con-
fidence intervals. Patients alive as of December 31, 
1993, were right censored at time of follow-up. A mul-
tivariate stepwise Cox's regression analysis (backward 
elimination method) was performed to identify factors 
that were independently associated with tumor recur-
rence and mortality. A p value <0.05 was considered 
statistically significant. 
RESULTS 
The overall survival was 91 % at 1 year, 43% at 3 
years, and 320/0 at 5 years (Fig. 1). Median survival was 
33 ± 2.2'( ± SE) months. There were no deaths within 
the first 30 days of operation and only two deaths (1 0/0) 
within the first 120 days. As of December 1993,7'2 of 
the 204 patients were alive and 50 patients were disease 
free at a mean of 65.1 ± 32.4 months (median, 62.5 
months) after hepatic resection. Twenty-two patients 
were alive with recurrent disease at a mean of 
20.7 ± 12.9 months (median, 18.5 months). Death with 
recurrent disease occurred in 124 (61 0/0) patients. Eight 
(4%) patients died free of disease at a mean of 
27.9 ± 30.9 months (median, 13.5 months) after he-
patic resection. 
Clinical risk factors and primary tumor charac-
. teristics. The actuarial overall and disease-free survival 
51'r 
34 
34 
35 
41 
28 
20 
36 
35 
37 
52 
31 
42 
53 
28 
26 
40 
31 
34 
alsease~li"etD suruival (%, 
Bres!ozi' 7 vr 3 yr 5 vr BreslO1C' 
65 29 ,-_J 
P = 0.361 71 32 27 P = 0.041 
54 ?" ~:> 20 
P = 0.037 60 31 26 !J = 0.25 
69 29 24 
P = 0.185 59 24 24 P = 0.116 
55 30 30 
60 27 21 
72 29 18 
91 45 40 
P = 0.045 59 27 25 P = 0.022 
78 35 26 
P = 0.053 77 41 34 P = 0.033 
60 26 20 
60 25 25 
P = 0.904 64 37 26 P = 0.536 
65 27 24 
64 25 25 
rates, stratified according to patient and primary tumor 
characteristics, are shown in Table 1. Gender, incre-
mental disease-free interval, site of primary tumor, 
and Dukes' stage were not correlated with patient sur-
vival. Patients older than 60 years of age and patients 
with a less than 24-month interval between color ectal 
and hepatic resection experienced a poorer outcome 
(p < 0.05). 
When disease-free survival rates were examined, men 
appeared to have longer recurrence-free survival. Early 
primary tumor stage (Dukes' A or B) and more than 
24-month interval between colorectal and hepatic re-
section were also found to be associated with longer dis-
ease-free survival. The remaining factors were not 
found to be significant predictors of disease-free survival 
when subjected to univariate analysis (Table I). 
Pathologic risk factors for colorectal hepatic me-
tastases. A number of hepatic metastasis features were 
found to affect patient and disease-free survival (Table 
II). The size (largest diameter) and differentiation of the 
metastatic tumor did not influence outcome when sub-
jected to univariate analysis. 
Patients with unilobar disease experienced superior 
patient and disease-free survival when compared with 
patients with bilobar disease (p < 0.0001). Of the 80 
patients with bilobar disease, 52 (65%) had lesions re-
quiring trisegmentectomy. The remainder underwent 
'I ~ 
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Table II. Pathologic and operative risk factors for overall and disease-free survival 
Overall survwal (%) Disease-free survival (%) No. oj 
patients 7 Yr 3 Yr .5 Yr Breslow 7 Yr 3 Yr .5 Yr Breslow 
No. of metastases 
1 91 89 
95 
88 
56 
41 
29 
45 P = 0.003 72 
66 
46 
40 
28 
10 
33 
28 
3 
p = 0.0003 
2-3 73 30 
2:4 40 19 
Tumor size* 
J cm 79 ')4 
88 
92 
51 
44 
32 
38 jJ = 0.231 65 
65 
62 
34 II = (J308 
5-9.9 cm 99 
10-20 cm 40 
Differentiation 
35 
22 
27 
19 13 
Well 53 91 
92 
90 
51 
39 
46 
40 P = 0.932 67 
67 
62 
40 
25 
23 
35 
22 
20 
p = 0.534 
Moderate to well 60 29 
Moderate to poor 89 33 
Tumor distribution 
Unilobar 124 92 
89 
55 
31 
44 P < 0.0001 72 
53 
35 
18 
31 
15 
p = 0.0002 
Bilobar 80 
Hepatic resection 
Wedge, LLS 
Lobectomy 
Trisegmenteetomy 
Multiple wedge 
Resection margin 
>1 em 
::51 em 
Involved 
Lymph node status 
Negative 
Positive 
Extrahepatic disease 
No 
Yes 
mTNM stage 
Stage I and II 
Stage III 
Stage IVA 
Stage IVB 
LLS, Left lateral segmentectomy. 
*Greatest diameter. 
25 
115 
55 
9 
95 
92 
17 
198 
6 
184 
20 
68 
43 
67 
26 
92 
91 
87 
100 
89 
92 
88 
90 
100 
92 
75 
93 
98 
88 
81 
53 
49 
36 
33 
55 
43 
12 
47 
o 
49 
15 
70 
49 
31 
12 
19 
46 
39 
21 
o 
42 
32 
o 
35 
o 
38 
o 
60 
33 
22 
o 
extended lobectomy (3), lobectomy plus wedge resection 
(16), or multiple wedge resections (9). 
A positive resection margin was associated with an 
extremely poor outcome with a patient survival rate of 
880/0 and 12':'0 at 1 and 3 years, respectively. Most pa-
tients with positive margins had major hepatic resec-
tions (seven lobectomies, eight trisegmentectomies), and 
13 (76%) of 17 had bilobar disease. Patients with resec-
tion margins of I mm to 1 cm and greater than 1 em had 
similar ,)-vear patient and disease-free s1l'dvival rates. 
The extent of hepatic resection was associated with 
disease-free survival (p = 0.014); however., it was only 
marginally associated with patient survival (p = (lOSS). 
;vIost patients underwent right or left lobectomy 
(n = 115). The second lar~est group (n = 54) under-
p = 0.058 
p = 0.005 
p < 0.00001 
p < 0.00001 
76 
69 
50 
67 
69 
63 
47 
65 
50 
68 
30 
80 
72 
55 
38 
55 
30 
20 
11 
36 
29 
o 
30 
o 
33 
o 
49 
34 
19 
o 
49 
24 
17 
o 
29 
25 
o 
26 
o 
28 
o 
40 
26 
19 
o 
p = 0.014 
p = 0.0062 
p < 0.00001 
p < 0.00001 
went either right or left trisegmentectomies. These two 
groups of major hepatic resections had 5-year survival 
rates of 39% and 21 %, respectively. The bilobar tumor 
distribution of 16 patients required wedge resections in 
addition to lobectomy. The median survival in these pa-
tients was 18 months, which was considerably worse 
than the 43-month median survival rate for those 
requiring lobectomy alone (p < 0.0001). Patients with 
minor resections Ewed~e resection and left lateral seg-
mentectomy) had expectedlv higher J-vear patient and 
disease-free survival rates of 46% and 49%. respectively. 
Those who required multiple wedge (or segmental) re-
section (n = 9) fared significantly worse with a 3-vear 
survival rate of onlv 330/0 and none at J vears (p < 0.05). 
A.ll of these patients had bilobar disease. and one third 
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Table III. Intraoperative transfusion and patient survival 
Actuarial oucral! sUTuzual (%) Hepatlc resection typc* 
No. 0/ vVedge. ilIultlple 
pallents 7 Yr 3 Yr .5 }r Bl·eslm.:' LLS RL. LL RTS. LTS zl)t'dge 
No transfusion 40 90 -.-, ::>- 46 p = 0.776 15 17 4 4 
Transfused 
1-25 units 141 92 43 33 P = 0.730 6 88 45 2 
1-5 l:nits 100 93 41 3:' 4 64 30 2 
6-10 Units 29 93 55 41 2 19 8 
>10 Units 12 83 31 0 5 7 
*LLS. Left lateral segmentectomy: RL. right lobectomy; LL. left lobectomy; RTS. righ' trisegmentectomy; LTS, lei' tClSegmentectomy . 
had positive margins or involvement of adjacent struc-
tures. 
The number of metastatic tumors in the liver was 
found to be associated with both disease-free and patient 
survival. Patients with solitary lesions fared best with a 
5-year survival of 45%. Survival rates for patients with 
multiple tumors, especially those with four or more, 
were significantly less (p < 0.003). Of the 40 patients 
with four or more lesions there were four patients with 
positive margins and six patients with nodal involve-
ment or extrahepatic disease. The majority (29 of 40, 
73%) had bilobar disease, and 37 required m<ljor hepatic 
resections (22 lobectomies and 15 trisegmentectomies). 
Data on intraoperative transfusion were available for 
182 of the 204 patients. The mean transfusion require-
ment for hepatic resection in this series was 3.68 units 
( ± 4.1 units) of packed red blood cells with a median of 
3 units. Forty patients (20%) did not receive a transfu-
sion. Most of these patients underwent wedge resection, 
left lateral segmentectomy, right lobectomy, or left 
lobectomy (Table III). Almost all patients requiring 
blood (1 or more units) underwent major hepatic resec-
tions (78 right or left lobectomies, 45 trisegmentecto-
mies). When subjected to univariate analysis, there was 
no significant difference in survival (p = 0.776). The 
5-year survival rates of patients receiving 0, 1 to 5, and 
6 to 10 units of blood were similar at 46%, 35'70, and 
41 %, respectively. 
Proposed modified TNM staging system .. The in-
terrelationship between tumor distribution, number of 
metastases, tumor size, and disease not confined to the 
liver was examined in accordance with a proposed 
TNM staging system for metastatic colorectal cancer 
(mTNM). (Table IV). Unilobar disease is confined to 
stages I through III, with bilobar disease and disease 
outside the liver comprising stages IV A and IVB, 
respectively. The actuarial patient and disease-free 
survivals correlated well with the proposed mTNM 
staging system (Fig. 2). Patients with stage I and II dis-
ease (n = 67) had the best patient and disease-free sur-
vival at 5 years of 61 % and 40%, respectively (p < 
Table IV. Proposed mTNM staging for hepatic 
colorectal metastases 
Classification 
Stage I mT1 NO MO 
Stage II mT2 NO MO 
Stage III mT3 NO MO 
Stage IVA mT4 NO MO 
Stage IVB AnymT Nl MO,Ml 
NO, Nl Ml 
m T7, Solitary :$2 em; m n, solitary >2 em, unilobar; multiple, :$2 em, uni· 
lobar; mT3. multiple, >2 em, unilobar; mT4, solitary or multiple, bilobar, in-
vasion of major branch of portal or hepatic veins or bile ducts; N7, 4bdominal 
I ymph node; M7, extra hepatic metastases or direct invasion to adja<;ent organs. 
0.0001) (Table II). Patients with extrahepatic lymph 
node involvement or invasion of contiguous structures 
experienced expectedly poorer survival rates, and re-
current (or perhaps persistent) disease was ubiquitous. 
Multivariate analysis. Tumor size, unilobar or bi-
lobar disease, and lymph node involvement were ex-
cluded from the multivariate analysis because the com-
bination of these factors defines mTNM staging. They 
were excluded to avoid problems related to multicollin-
earity of risk factors. 15 The results of the multivariate 
analysis of mortality and tumor recurrence are shown in 
Tables V and VI, respectively. The following factors 
were found to be independently associated with tumor 
recurrence: number of tumors (four or more), involved 
margins, and mTN!vI stages IV A and IVE. Similar re-
sults were obtained when analyzing mortality. Involved 
margins and stages IVA and IVB disease were found to 
be independent prognostic factors. Stage III disease was 
also found to be significant, whereas the remaining fac-
tors previously examined were not found to be signifi-
cant in a multivariate context. 
DISCUSSION 
A number of staging systems have been described for 
metastatic colorectal cancer to the liver. 16-19 Each has 
supportive data that have promulgated their use as sig-
(' 
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Fig. 2. Overall and disease-free survival rates after hepatic resection for metastatic colorectal cancer according 
'to proposed mTMM staging system. (--, stages I and II (n = 67); .... , stage III (n = 43); ---- stage IVA 
(n = 68); -. e- stage IVB (n = 26). 
Table V. Relative risk of mortality with Cox's proportional hazards model 
Univariate 95% confidence limits 
Adjusted lVluLtivariate 95% confidence limits 
Variable RR Lower Upper 
Age (2::60 yr) 1.41 0.99 1.99 
Interval (>24 mo) 0.73 .050 1.06 
Tumor no. (2::4) 2.24 1.43 3.49 
Resection type 
RTS, L TS + multiple wedge 1.59 1.12 2.26 
Resection margin, involved 2.52 151 4.21 
Dukes' stage 
B 1.82 1.15 2.86 
C 2.02 1.23 3.32 
m T:-JM stage 
III 1.85 109 3.12 
IVA. 2.95 1.85 4.71 
IVB 5.47 3.14 9.53 
nificant prognosticators bv their respective authors. 
Cnfortunatelv. no svstem has been widely adopted to 
allow comparisons among studies. The application of 
Fortner's revised staging sYstem to our series would re-
sult in the vast majority of patients being categorized JS 
stage I because of the small number with regional or 
p Value RR Lower Upper p Value 
.037 
0.101 
<0.001 
0.010 
<0.001 1.90 1.12 3.21 0.017 
0.010 
0.005 
0.022 1.73 1.01 2.94 0.043 
<0.001 2.69 1.67 4.34 <0.001 
<0.001 5.20 2.97 9.09 <0.001 
extrahepatic disease (stages II and III).17 Our present 
analysis supports the further staging of disease confined 
to the liver (with complete extirpation) and its prognos-
tic significance. Gennari et alKl~ and Doci et a1. l <1 sug· 
gested the use of a svstem more akin to TNM staging 
that took into account multiplicity and distribution. but 
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Table VI. Relative risk of disease recurrence with Cox's proportional hazards model 
L'nivariate 95% con ridcllcc ilmlls 
ridjusted iHultiuanate 95% crmjidence izmlts 
r 'anable RR Lower Upper 
Tumor no. (:2:4) 2.22 1.52 3.2-+ 
Interval (>24 mol 2.22 0.54 1.08 
Female gender 1.32 0.95 1.85 
Resection tvpe 
RL,LL 1.72 0.94 3.15 
R TS, L TS + Multiple wedge 2.51 1.34 4.72 
Resection margin involved 2.60 1.55 4.38 
Dukes stage 
B 158 1.05 2.39 
C 1.55 0.98 2.44 
mTNM stage 
Stage III 1.51 0.93 2.45 
Stage IVA 2.25 1.47 3.43 
Stage IVB 3.96 2.37 6.62 
the extent of liver involvement (percentage of paren-
chymal disease) was used rather than tumor size. We 
believed that tumor size, as measured in centimeters 
(maximum nodule diameter), and unilobar or bilobar 
involvement were more readily reproducible and appli-
cable. After we analyzed the commonly reportedpoten-
tial risk factors influencing survival and recurrence, we 
applied a proposed mTNM staging system for hepatic 
metastatic tumors (Table IV). In our series of 204 pa-
tients the correlations to both overall and disease-free 
survival were shown to be highly statistically significant. 
In addition, the variables used in the staging system 
were all significant prognosticators when subjected to 
univariate anal ysis. The interrelationship among tumor 
size, multiplicity, and distribution is well illustrated by 
the proposed mTNM staging system, and it in turn re-
flects the influence of tumor burden on patient survival. 
A number of studies have suggested that the presence 
of four or more metastases is a particularly adverse 
prognostic factor, but this has not been a consistent ob-
servation. 5.7,13,16.20-22 In our previous reportS we had 
only seven patients with [our Or more lesions, and none 
survived more than 3 years. However, the results of this 
current analysis are statistically more compelling. The 
observed 200/0 .=i-year survival rate of these patients ar-
gues against considering this an absolute contraindica-
tion to resective therapy. In contrast to the findings of 
Scheele et al.,4 we found that bilobar distribution of 
metastases had a significant deleterious effect on overall 
and disease- free survival. Interestingly, 29 of 40 patients 
with four or more lesions had bilobar disease as did the 
majority of patients with large metastases (10 to 20 em). 
Consideration of tumor size alone did not reveal prog-
.nostic significance, but the consequences of size with re-
'spect to tumor distribution and requirement for more 
p Value RR Lower Upper p T"alue 
<0.001 1.84 1.25 2.70 0.002 
0.124 
0.D98 
0.081 
0.004 
<0.001 2.34 1.37 4.01 0.002 
0.028 
0.061 
0.094 
<0.001 1.55 1.06 2.27 0.023 
<0.001 3.01 1.88 4.83 <0.001 
extensive (bilobar) resections were observed to be 
important. 
A multi institutional retrospective review from the 
Registry of Hepatic Metastases found that resection 
margins of less than or equal to 1 cm had a negative ef-
fect on long-term survival. It is notable that res~ction 
margins were not available for most patients in their se-
ries and patients with positive margins were grouped 
with those having margin widths of 1 ern or less.7 When 
grouped separately we found no significant difference in 
survival rates unless the margin exhibited residual tu-
mor. A positive resection margin was a powerful 
predictor of patient survival and recurrence in both a 
univariate and multivariate context. These observations 
were not surprising because residual tumor constitutes 
surgical treatment failure from the outset and outcome 
is expectedly poor. 
Some reports have observed lower survival rates in 
older patients, but they did not approach statistical sig-
nificance.S,7 Although we found that patients who were 
older thaJa 60 years had somewhat poorer survival rates, 
the risk of recurrence was similar to those younger than 
60 years of age. 
The metastasis-free interval after resection of the 
colorectal primary tumor appears to be an important 
prognostic factor. The Registry of Hepatic Metastases 
study by Hughes et al.7 found that a disease-free inter-
val of less than 1 year was associated with inferior sur-
vival rates. Our analysis of incremental increases in 
disease-free interval revealed a trend for improved sur-
vival with increasing time. Patients with disease-free 
intervals of more than 24 months had superior overall 
and disease-free survival rates. It would appear that a 
longer metastasis-free interval connotes more favorable 
tumor biology and outcome. 
-. 
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In contrast to other previously reported studies we did 
not find metastatic tumor size, Dukes' stage, tumor dif-
ferentiation, or amount of blood transfused to be signif-
icant prognostic factors. 6, 7.11,16,19,20,23 
The data from this updated series of hepatic resec-
tions for metastatic colorectal cancer affirm our resolve 
to continue an aggressive surgical approach to this dis-
ease. In addition to examining the influence of tradi-
tionall y reported prognostic Cactors we classified our 
patients with a simple mTNM staging system. The re-
sultant analysis revealed this staging system to be a sig-
nificant prognosticator for both survival and recurrent 
disease. Its application would more readily allow com-
parisons among studies and allow for prospective eval-
uation of the staging criteria and the role of adjuvant 
treatment strategies. Further refinements of staging cri-
teria could evolve to include biologic, molecular, or ge-
netic factors in addition to the anatomic extent of 
disease, which is the primary basis for TNM staging at 
present. 
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DISCUSSION 
Dr. James W. Williams (Chicago, Ill.). During the past 20 
years or so a number of surgical investigators have collectively 
defined what we can expect from the biologic behavior of co-
lon cancer when it spreads to the liver. What they have shown, 
I believe, is that a subset of colon cancers finds access to the 
portal bloodstream, lodges in the liver, finds a suitable envi-
. ronment, and can survive there in the absence of tumor any-
where else. Perhaps as many as 20% of patients who have co-
lon cancer at some time during the course of their disease, ei-
ther at autopsy or during the course of their illness, will have 
metastatic tumor isolated to the liver. This group and others 
have shown and this paper very eloquently illustrates that in 
a high percentage of patients the patient will be cured if you 
successful! y remove the tumor. 
The problem now is what to do with the group of patients 
with hepatic metastasis who we now can predict very accu-
rately are not cured. One of the strengths of this paper is that 
it has shown that you can accurately predict which patients 
have a high risk of death from their primary disease despite 
a very skillful liver resection. 
As surgeons who deal with this condition we now are 3t a 
crossroads or maybe at a time of new opportunities. With the 
molecular biologists describing various cytokines and biolog-
icals that influence the immune system and the endothelial 
cells of our bodies. it is important for us as surgeons to be aware 
of some of this. 
I want to illustrate what I think is enough of an unusual 
situation to justifv a mini case repon. The patient was a .[8-
"ear-old man who was found to have an obstructing colon 
cancer and I 0 or 12 [Umor implants throughout the li\er. 
Clear! v this patient had a limited chance of long-term surVivaL 
Vlie removed his tumors. which required :t nonanalOmic re-
• ( 
I 
".i· 
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section of the posterior segment of his right lobe. and 10 or 12 
oftheselesions were removed from the rest of his liver. He was 
started on an aggressive course of a-interferon and S-fluor-
ouacil. This was almost 4 vears ago, and as far as we can tell 
this patient is free of cancer. 
a-Interferon is a very potent drug that is able to clear a 
number of patients with chronic hepatitis B and to make them 
antigen negative, may be very effective in chronic hepatitis C, 
and has a number of effects on the immune system, endothe-
lial cell function, and the expression of major histocompati-
bility complex molecules. 
I am obviously not proposing this as a cure for cancer of the 
colon when it metastasizes outside the liver but just use this to 
illustrate the body of knowledge that is rapidly evolving in the 
laboratories of our basic scientist colleagues. As surgeons we 
must have the vision to exploit the potential of these powerful 
evolving molecules. 
Dr. Ralph J. Doerr (Buffalo, N.Y.). In the patients who 
experience a recurrence after resective surgery for colorectal 
metastasis to the liver, one half of the patients again exhibit 
liver metastasis and one half have recurrences outside the liver. 
Could you tell us the pattern of failure in your patients and 
whether you undertook a second reresective effort? A number 
of reports have shown efficacy in reresecting a presumed iso-
lated liver metastasis after initial curative resection. 
With the poor survival data in the subset of patients who 
had contiguous involvement or lymph node positivity, would 
you recommend not resecting the liver in those patients? Per-
haps when a gastroduodenal, periportal, or celiac lymph node 
is positive, the best course is to try another modality such as 
alcohol ablation or cryoablation. 
Finally, is there any role for hepatic artery catheters in those 
otherwise desperate cases? 
Dr. David Qtta (Columbia, Mo.). I support Dr. Williams' 
comments. Our medical oncology colleagues have made 
significant progress with systemic chemotherapy. They have 
not conquered this disease, but certainly they are starting to 
see partial remissions with chemotherapy regimens such as 
5-fluorouracil, a-interferon, and leucovorin. 
You have presented nice data as to who is at high risk to fail 
surgical resection. If you can determine stage IV disease be-
fore operation with laparoscopy and computed tomographic 
scanning, would these patients benefit from preoperative che-
motherapy and if they respond, would you then proceed with 
surgical resectiqn? 
Dr. Gayowski (closing). Dr. Williams asked how we treat 
patients whom we have identified at high risk for recurrence. 
In the past Dr. Iwatsuki and Dr. Starzl have advocated the use 
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of chemotherapy for most patients after hepatic resection. Our 
previous experience suggested that patients receiving pos-
tresection therapv experienced improved survival and disease-
free intervals. Now that we can identify patients who are at 
low and high risk for recurrence. I think we can develop bet-
ter strategies to implement neoadjuvant therapy. 
Unfortunately, we don't have very many chemotherapeutic 
agents that have consistently been shown to be efficacious for 
this disease. :i-Fluorouracil was mentioned, some of the new 
immunomodulators are coming into the forefront, and perhaps 
a combination of these therapies is warranted. 
Patients identified as being at high risk for recurrent disease 
should receive some form of neoadjuvant therapy. Random-
ization to one form or route of therapy versus another would 
be appropriate. We do not believe that the null hypothesis is 
satisfied here, and a clinical trial should not include a null 
treatment arm. 
I think we have all had anecdotal cases of patients who 
"haven't read the textbook" and survive in defiance of the odds 
and what we know from experience. This reflects the capri-
cious nature of this disease and illustrates the many other as-
pects of tumor biology that we cannot see at the time of op-
eration. 
Dr. Doerr, in looking at patients who undergo resective 
therapy, roughly one half of our patients experienced recur-
rence in the liver and the other half had extrahepatic disease. 
We had a small proportion of patients with isolated hepatic 
recurrence and a small number, probably three or fQUr, un-
derwent reresection for these. I don't have survival ,data for 
these patients readily available. We also had two patients with 
pulmonary metastases that were resected. One patient even-
tually succumbed to disease and one patient is still alive. 
With respect to patients with nodal or contiguous disease, 
in Dr. Iwatsuki's early experience there was always an 
attempt to remove the tumor as long as it was confined or 
appeared to be confined to the liver. A lot of the contiguous 
disease cases had microscopic spread discovered after patho-
logic examination. In some cases surgical momentum dictated 
the outcome. There were a few young patients with nodal 
disease high in the hilum, and a decision was made to pro-
ceed with resection in an effort to offer some hope in an oth-
erwise desperate situation. There were only six patients with 
positive nodes in ·the entire series. Ordinarily we would not 
proceed with resection in patients with lymph node metasta-
ses. 
Dr. Otta, we have not used the staging system to stratify 
high-risk patients into a preoperative systemic chemotherapy 
protocol; however, this is an attractive proposal. 
.\: 
.; 
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Letters to the editors 
staging of resectable coloredalliftr metal ... ~ 
To the Editors: 
Dr. Gayowski et al,l have presented a cOOBeCutive series of 
204 patients who underwent resection of colocectal liver me-
tastases during an ll-year period. According to the summary, 
the procedures were "curatiw:", 
This analysis provides information on essential aspects such 
as length and rompleteness of follow-up, destiny and tumor 
slalus al the end of the study, and particularly the paramowll 
question of1IlaCl'OMXlpic and microscopic tumor clearance. It 
confirms our own obllervation that (1) tumor reCWTence after 
more than 5 years (7 years in our series) is extremely rare, (2) 
survival equals cJisease.free survival after this time, and (3) var-
ious factors proposed as absolute contraindications to resec-
tion such as four or more me1llStmies and limited resection 
margins (as long as they are clear) may serve as qualifiers 
but not predictors of sUJVival,2,3 It also confinntl the fact 
that histologicaIly involw:d resection margins do preclude 
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5-year suMvaI and result in very limited 3-year survival figures 
of 12%. which mirrors the natucal history of comparable pa-
tients. 4 
These histologically nonradica1 procedur~ (17 patients) 
should have been removed from the further analysis because 
involved margins clearly contradiCt the Union lntematiooale 
Contre Ie Cancer classification of a "curative" procedure.s 
Their indmion explains for weak results in various subgroups 
such as bilateral involvement (1 ~ po!litive margins/SO .,. 
ticnts) or triscgmentectomy (8 positive margins/55 patient5) 
and makes statistically based conclusions on the biologic im· 
pact of these criteria less convincing. 
The true problem of this articlc is the proposed staging sys-
tem. Factors proven important in primary liver cancer. pre-
dominantly in patients with cirrhosis, are simply transposed to 
a completely different biologic condition, namely mela5ta1k 
liver disea.'Ie. Designed to create a widely acceptable framework 
for a morc unifonn data analysis. this proposal is likely to fur-
ther increase the already existing confusion. The analysis of 
our own consecutive 350 patients who undetwent macroscop-
ically and microecopica1ly complete RO ("curative") resection 
fails to ascertain any validity of the new system in predicting ei-
ther crude or disease-free ~-af (Figure. A and B). This is 
surprising becaUlle the o-ver.ill results of the two series are quite 
similar. Their 5-fear survival of 32% matches our 33% in 
434 patients resected with curative intent, as docs the per-
centage for patients with dear margins. which is 37% in PiI.t5-
burgh (extrapolated from Table n) as opposed to 39% in 
Erlangen. The similarly extrapolated 27% disease-free SUT-
vival in Pittsburgh is not significantly different from 34% in OUT 
acrics.2 
Because the proposed staging system appears irrelevant in 
our database. which prelleDtIy comprises the largest single in-
stitution series worldwide, adoption by other groups may not 
solve the problem. Presumably a prospective data pooling by 
leading centers in the field. on the basis of a genera) coruen-
SUli on inclusion and exclusion criteria (such as operative 
deaths. involved margins. positive hilar lymph nodes). and 
adding modem cytobiology features to traditionally collected 
crileria may provide a basis to minimize the Babylonian 
languish. terminology, and finally staging confusion among 
scientists and clinicians. 
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Reply 
To the Editors: 
We thank. Dr. Scheele and his colleagua for their prompt 
reexamination of our proposed mTNM staging system on their 
large series of patients. 
FU'Sl, we would like to draw a.trention to our methodology 
section, which states that all procedures were attempts at cur-
ative resection. In our abstract summary "curative" was meant 
to refer to removal of aJJ macroscopic disease. and we apolo-
gize if this was misleading or disinformative. 
Set:um.l, we do not believe that exclusion of patients with 
microscopically involved margins (either parenchymal or in 
resected contiguous structures) would be appropriate. We 
agree that these represent surgical treatmentfailUJ't'S; however, 
if we excluded our treatment failures from our analysis. then 
we are truly biaJing our results. A! many have exPerienced. 
surgical momentum often dictates the outcome of major 
hepatic resections, and even with reIllO'Vll! of all macro-
scopic identifiable disease, we can expect "hisw!ogic nonrad-
ical" resections to occ:ur, albeit with an acceptably low fre-
quency. If we exclude these failures. then we are imposing 
bias in that the types of disease (bilobar) or extensive re-
section (trisegmentectmny) that are occasionally associated 
with positive microscopic margins (treatment failure) are ex-
cluded from analysis. We cannot ignore the biologic im-
pact of the consequences of tumor number. site. and size 
with respect to OUT ability [0 completely extirpate these le-
sions. 
Unfortunately, the application of our staging system did not 
appear to be IJ!ICfui in their series of patients. and hence its 
validity has been questioned Their swvival of stage 1/11 
patients was approximardy 40% at 5 years, significandy lower 
than our 60% rate. On the contrary. their reported survival of 
stage N B patients (tumors with lymph node or ex.tra hepatic 
invohrement) was lIO% at 5 years. as opposed to our 0% rate. 
We are surprised by the imprelfiive survival rates of patients 
with hilar-perihepatic nodal metastaIes and/or contiguous or 
extrahepatic disease because these patients typically do not 
fare well 
What might have au:ounted for these differences? Although 
we look. forward to seeing their new data (in press). we can only 
extrapolate from their previous publication (SURGERY 
1990; II 0: 13-29). In this repon approximately one third of pa-
tients were treated with wedge resection and another 22% with 
segmentectomies, which we categorize as wedge resections. In 
addition, approximately one third of the patienm had simul-
taneous colon and liver resection. This is in distinct contrast 
] 20 Letters to the editors 
to our series in which the use of wedge resection was 
exceptional (85% major hepatic resections) and simultaneous 
colon and liver resc:ction was rare. 
prrmllerhepatic~tionsE~eI~ddFnrighthave 
underestimated the tumor stage, panicularly when imaging 
techniques and intraoperatn'e oging strategies were evolving 
during the 1960s and 1970s.AIso, satellite tumor phenomenon 
W"dS not addrosc:d in OUT analysis. became we considered each 
lesion as independent. Hence, patienlll with a dominant lesion 
(larger than 2 em) and multiple satellites in one lobe could be 
incorrecdy classified as stage II in their series, again under~ 
timating the staging. 
Our proposed staging sy1tem is inadequate for the patienlll 
who unrlergo lIimultaneoUll colon and liver resection, be-
came 9}'Tlchronous lymph node inyll~ent in the colonic re-
gion (Cl. C2) classifies all of the hepatic metastatic tumon in 
stage IV B. Hepatic metastases should be staged after the rad-
ical colectomy i3 completed. Nodal and extrahepatic disease in 
OUT proposed system refers only to the "metastases of metal!-
tases" phenomenon. rather than primary nodal disease or 
concomitant local primary invaaion. If the 50 stage IV B 
patients in their series have a high incidence of remote extra-
hepatic disease (i.e.. pulmonary), then the reaullS are truly 
remarkable. 
We fully agree that prospecme data pooling and analy-
sis are essential to evaluate staging aiteria and refine or 
modify them further. The addition of cytobiologic featUreS, 
as well as molecular or genetic factors. will help WI better 
define the biologic phenomenon of colorecta1 n:tetastases 
(if such a thing is indeed available now) and better elucidate 
the impact of surgical and/or a4juvant treatment strate-
gies. 
T'11IUItky GayowsIIi. Mil 
5'AunzUu1O lwaLsUi, MD 
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Adequacy of stereoCDk: breaR biopIIiea 
To the Editors: 
I am responding to the article "Are Stereotaxic Breast Bio~ 
sies Adequate?" (SURGDl.Y 1994;116:610-5). 
FlTIt, Hernandez et aI. arbitrarily define specimen "inade-
quacy" as rare or scant breast epithelium in one or two core 
fragmenls. The presence of breast epithelium may have 1W re-
lationship to the mammographic lesion. For eumple, a per-
fectly "adequate" specimen may reflect fibroaia without duc-
tal epithelium. Adequacy. as they define it, is clinically irrele-
vant. 
Second, they confuse the term.ll fJrobabl"J bmiI(JI with ~ 
minalliesions, which leads to interesting but misinformed dis-
cwsion regarding the use of the m:hnology. As JJI(lIIt radiolo-
giSIS and infurmed ~ surgeonll are aware, the category of 
probably benign is wed in a mammographic: screening 
program to assign thooc lesions found at mammography with 
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an approximate 1 % or less likelihood of malignancy to peri-
odic mammographic surveillance, rwt biopsy.! 1be designa-
tion of probably benign i3 not assigned to lesions for which the 
decision to biopsy has been made. In practice, most of these 
lesions for which biopsy is recommended are indeed indeter· 
minate. given die few specific signs of malignancy available 
through mammography. It is emphasized that rarliologi!IU 
concentrate on recommending core biopsy only for lesions 
that otherwise would be managed with open surgical biopsy, 
excluding probably benign lesions where periodic imaging 
surveillance is a wcD-establishc:d management choice.2 It is in-
correct therefore that "before the advent of SCBB. most inde-
tenninate mammographic lesions were observed rather than 
excised," as Hernandez et aI. assert. 
The scientific and fiscal validity of the procedure are not 
suspect, indeed quite the opposite. Parker et a1.' demonstrated 
the reproducibility and reliability of this technique in a mul-
tiinstitutional study. One cannot call the use of excisional bi-
opsy for all mammographic lesions for which biopsy is recom-
mended as fiscally sound, given that there is generally on Iy a 
20% incidence of malignancy. FIVe biopsies to find one malig-
nancy is unacceptable from anyone's perspective. In fact. the 
use of stereotaxic Jarge-core breast biopsy instead of surgical 
biopsy would be "equally as accurate and would save the 
health-care system at least $1 hilliml a year ... • 
Third, uniformly obtaining only five core biopsy specimens 
is not currently clinically recommended. It is now weD estab-
lished that five cores is a minimum number and tha\ larger Ie-
siOJUl or lesions containing many calcifications reqUire many 
more than five core specimens.s 
F'maUy, I concur that frequently general surgeons are most 
experienced in the management of breast diaeaae-when it 
exists. Imponantly, ~eons are not trained in breast imaging 
or imaging guided procedures. as /l1Q8t radiologists are, and 
should become invoh'ed only at the appropriate clinica1junc-
ture. 'That is to say, a aurgica1 referral should be generated 
when ama.ss or ma1ignancy are proved orpoaaible. Thisafforda 
another area of cost saving in avoiding the layer of expense 
generated by unnecessary surgical referral when the mamm0-
graphic lesion is fuund to be benign. aa is mOlll frequently the 
case. 
The shifting paradigms of responsibility in breast disease di-
agnosis are understandably made with requisite suspicion and 
some lewl of animus. However, the transition is more effective 
when good communication and conaultation are promoted. A 
multidisciplinary approach (incorporating at 1ea.U: the radiol-
ogist, pathologist. and surgeon) to the technology and the pa-
dent is in the best interests of all parties. 
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